Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | TDP2 | O95551 | 6/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | YES1 | P07947 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41009 | 0.86 | LRRK2 (0.47) | SRCPDGFRBJAK2LRRK2 | |
| SCHEMBL41861 | 0.83 | SRC (0.53) | SRCPDGFRBTDP2JAK2JAK3 | |
| SCHEMBL41685 | 0.79 | TDP2 (0.35) | SRCPDGFRBTDP2JAK2JAK3 | |
| SCHEMBL41597 | 0.75 | LRRK2 (0.47) | SRCPDGFRBJAK2JAK3LRRK2 | |
| SCHEMBL41638 | 0.71 | PIK3CG (0.43) | SRC | |
| SCHEMBL615141 | 0.71 | SRC (0.62) | SRCPDGFRBJAK2JAK3YES1 | |
| SCHEMBL613388 | 0.71 | LRRK2 (0.47) | SRCPDGFRBJAK2LRRK2ABL1 | |
| SCHEMBL612688 | 0.70 | LRRK2 (0.44) | SRCPDGFRBJAK2JAK3LRRK2 | |
| SCHEMBL41122 | 0.69 | SRC (0.53) | SRCPDGFRBJAK2LRRK2 | |
| SCHEMBL612670 | 0.69 | SRC (0.45) | SRCPDGFRBJAK2JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | claimed |
| EP-2585439-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2013-05-01 | — | — | EP | claimed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | claimed |
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | disclosed |
| EP-2585439-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | CAMK2D, CAMK2A, CAMK2B | SRC 401/4885PDGFRB 803/4885TDP2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.